Our results clarified that intranasal administration of D-Pen mainly upregulated ADAM10 expression to achieve better therapeutic effects against AD, which was via MTNR1α and stimulated the PKA/ERK/CREB pathway. Here, CREB1 is linked to Alzheimer disease.